

This itinerary of **Highlights for a General Audience** has been curated by the **Alzheimer's Association Medical and Scientific Relations team** to highlight the content that is most accessible to a **general audience**.

Sessions are listed in Central European Summer Time (Amsterdam).

Schedule is current at the time of posting. Titles are listed as submitted.

All sessions listed are hybrid and can be viewed live by both in-person and online attendees. Recordings will be available immediately and accessible to watch online for 30-days.

Plenary Sessions

Hear updates from the Alzheimer's Association and learn about the state of the field from a leading expert. All plenary sessions are in Hall 5

Date and Time	Session
Sunday, July 16 11:15 a.m.	Tau PET: Towards Implementation In Trials And Clinical Practice. Rik Ossenkoppele
Monday, July 17 11:15 a.m.	Bassoon Contributes To Tau-seed Propagation And Neurotoxicity. Cristian Lasagna-Reeves The Evolving Role of Complement In Alzheimer's Disease. Cynthia Lemere
Tuesday July 18 11:15 a.m.	The Aphasic Dementia Of Alzheimer's Disease. Marsel Mesulam The Epidemiology Of Dementia In Africa. Adesola Ogunniyi
Wednesday, July 19 11:15 a.m.	Amyloid Reduction And Evidence Of Downstream Biomarker Modification. Rachele Doody, Michael Irizarry, Jared Landen, John Sims
Thursday, August 4 9:45 a.m.	An Agenda For Addressing Multimorbidity And Racial And Ethnic Disparities. Ana Quiñones Inclusion in Research and Clinical Trials. Goldie Byrd

Scientific Sessions

Attend sessions and engage in live discussion.

Date, Time & Location	Session
Sunday, July 16 8:00 a.m. Hall 10	LEADS: Scientific Advances In Sporadic Early-Onset Alzheimer's Disease <ul style="list-style-type: none"> Midpoint baseline results of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) - Dustin B. Hammers The Sporadic Early-Onset Alzheimer's Disease Signature of Regional Atrophy - Alexandra Touroutoglou Amyloid-PET, tau-PET, and their association in sporadic early-onset Alzheimer's Disease: Cross-sectional and longitudinal data from the LEADS study - Renaud La Joie Investigating the Genetics of Sporadic Early-Onset Alzheimer's Disease - Kelly N. H. Nudelman Exploring the Utility of Biofluid-Based Biomarkers in Early-Onset Alzheimer's Disease - Jeff L. Dage
Sunday, July 16 9:15 a.m. Hall 12	The Role Of Early Life Adversity In Cognitive Decline And Dementia <ul style="list-style-type: none"> The association of childhood socio-economic position with later life brain structure in individuals of Hispanic/Latino background. Preliminary results from the INCA-MRI study - Paola Filigrana Persistent financial adversity across adulthood and cognitive ageing: A lifecourse investigation - Yiwen Liu Life course financial mobility and later-life memory function and decline by gender and race/ethnicity: an intersectional analysis of a multi-ethnic cohort study - Lindsay C Kobayashi Early life factors and individual differences in the brain through the human lifespan – association of intercept or change? - Kristine B Walhovd Determinants of Cognitive Trajectories in Lower Educated Older Adults: Evidence from Brazil - Fabiana Ribeiro Pathways linking educational attainment to cognitive functioning among older Brazilians - Mateo Farina
Sunday, July 16 9:15 a.m. Elicium 2	Meaningfulness of Clinical Trial Outcomes in Alzheimer's Disease: Translation of Results to Patients <ul style="list-style-type: none"> Estimating Treatment Effects of Disease-modifying Drugs: Traditional Methods vs. Accelerated Failure Time Models and Progression Analysis - Lars Lau Raket Incorporating clinical trial outcomes in health economic evaluations of disease-modifying therapies for AD - Linus Jönsson Changing the trajectory of Alzheimer's disease: What is a meaningful delay in disease progression? - Krista L. Lanctôt Translating AD Clinical Trial Results to Meaningful Benefits: Expectations, Definitions, Challenges and Opportunities - Alireza Atri
Sunday, July 16 2:15 p.m. Hall 11	Diversity-Informed Approaches To Dementia Care <ul style="list-style-type: none"> "It's my life, it's my choice and I want to say when" vs "A good death is to be on good terms with God". Comparing the views of people with dementia in the UK and Brazil about a good death: Qualitative study - Edison Iglesias de Oliveira Vidal Social support, plasma amyloid, and cognitive function: Findings on cognitive resilience from the African Americans Fighting Alzheimer's in Midlife (AA-FAIM) study - Megan Zuelsdorff Supporting ADRD care partners from historically and currently underserved communities - Walter D Dawson "It's a lonely journey": Personal experiences and psychosocial distress among Chinese American dementia family caregivers - Y. Alicia Hong Development of Moving Pictures GENIE-an online gateway to dementia resources to support Culturally and Linguistically Diverse (CALD) communities - Josefina Antoniadis Pre-diagnostic symptoms of young-onset dementia in the General Practice - Stevie Hendriks

<p>Sunday, July 16 2:15 p.m. Hall 5</p>	<p>Learnings From GRADUATE I & II: Paving The Way For Future Therapeutics In AD</p> <ul style="list-style-type: none"> GRADUATE I AND II: Revisiting the key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer's disease (AD) - Christopher Lane GRADUATE I AND II: Factors that may influence participant response to subcutaneous gantenerumab - Angeliki Thanasopoulou GRADUATE I and II: Subgroup analysis and correlations of biomarkers with exposure - Tobias Bittner
<p>Sunday, July 16 4:15 p.m. Hall 5</p>	<p>NIA-AA Revised Clinical Criteria for Alzheimer's Disease</p>
<p>Monday, July 17 9:15 a.m. Hall 12</p>	<p>Hearing Loss And Dementia: Cause, Consequence Or Catalyst?</p> <ul style="list-style-type: none"> Role of Hearing-Health-Care Professionals in supporting Patients with Dementia Risk - Dona Jayakody Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology - Jin-Tai Yu Dementia is an auditory brain disorder - Jason D Warren A Europe-wide randomised controlled trial of hearing and vision rehabilitation in dementia: Additional findings from the SENSE-Cog trial - Iracema Leroi
<p>Monday, July 17 2:15 p.m. Elicium 2</p>	<p>Psychiatric And Neuropsychiatric Syndromes</p> <ul style="list-style-type: none"> Common neurobiological mechanisms underlying anosognosia and neuropsychiatric symptoms across the Alzheimer's disease spectrum - Geoffroy Pierre Gagliardi Increased Genetic Risk for ADHD Potentiates Cognitive Impairment and Brain Hypometabolism in Alzheimer's Disease Patients - Douglas Teixeira Leffa Apathy, empathy and depression in Alzheimer's disease and frontotemporal dementia: Examining the constructs and white matter correlates - Halle Quang Elevated Tau burden in Amygdala and Hippocampus amongst older participants with psychosis - Aubrey S. Johnson Psychometric evaluation of the German version of the Mild Behavioural Impairment Checklist (MBI-C) - Jessica Grothe Structural brain network degeneration associated with agitation in dementia - Lisanne M Jenkins
<p>Monday July 17 2:15 p.m. Hall 5</p>	<p>Anti-Amyloid Treatment In Asymptomatic Alzheimer's Disease (A4) and Longitudinal Evaluation Of Amyloid Risk And Neurodegeneration (LEARN) Study Longitudinal Results</p> <ul style="list-style-type: none"> Anti-Amyloid treatment in Asymptomatic Alzheimer's disease (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study Longitudinal Results - Reisa A. Sperling
<p>Monday, July 17 4:15 p.m. Hall 5</p>	<p>Donanemab In Early Symptomatic Alzheimer's Disease: Efficacy And Safety In TRAILBLAZER-ALZ 2, A Phase 3 Randomized Clinical Trial</p> <ul style="list-style-type: none"> Introduction - Mark A. Mintun Clinical Background and Study Design - Paul Solomon Efficacy Results from TRAILBLAZER-ALZ 2 - John R. Sims Safety Results from TRAILBLAZER-ALZ 2 - Steven Salloway Imaging and Biomarker Assessments from TRAILBLAZER-ALZ 2 - Oskar Hansson Contextualizing the TRAILBLAZER-ALZ 2 Results - Liana G. Apostolova
<p>Monday, July 17 4:15 p.m. Hall 12</p>	<p>Sleep And Brain Health: Associations And Mechanisms</p> <ul style="list-style-type: none"> Short sleep duration and hypertension: A double hit for the brain - Stephanie Yiallourou 24-hour rest-activity rhythms and light exposure patterns in relation to cognitive function in a nationally representative U.S. sample - Qian Xiao Sleep Patterns and Prospective Diffusion Weighted Imaging Biomarkers: the Sleep and Dementia Consortium (SDC) -

	<p>Andree-Ann Baril</p> <ul style="list-style-type: none"> • Sleep breathing patterns and neurocognitive function in a diverse Hispanic/Latino cohort - Kevin A González • Protective effects of sleep duration and physical activity on cognitive performance are influenced by β-amyloid and brain volume but not tau burden among cognitively unimpaired older adults - Vahan Aslanyan • Multimodal investigation of the early associations between sleep-wake regulation, cognition and Alzheimer's disease neuropathology and risk - Vandewalle Gilles
<p>Tuesday, July 18 8:00 a.m. Hall 10</p>	<p>Effects Of Hearing Intervention On Cognitive Decline And Brain Health: Results Of The Aging And Cognitive Health Evaluation In Elders (ACHIEVE) Randomized Trial</p> <ul style="list-style-type: none"> • Effects of hearing intervention on cognitive decline and brain health: Results of the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) randomized trial - Frank R Lin
<p>Tuesday, July 18 8:00 a.m. Hall 11</p>	<p>The U.S. Study To Protect Brain Health Through Lifestyle Intervention To Reduce Risk (U.S. POINTER)</p> <ul style="list-style-type: none"> • Background and Design of the U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk (U.S. POINTER) - Laura D Baker • (University of California, CA, USA) - U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER): Baseline Characteristics of a Trial Cohort Enriched for Risk of Cognitive Decline - Rachel A. Whitmer • Development and Validation of the Modified Neuropsychological Test Battery (PmNTB) in the Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) - Kathryn V. Papp
<p>Tuesday, July 18 9:15 a.m. Hall 12</p>	<p>Non-Pharmacologic Risk Reduction Strategies For Alzheimer's Disease: One Size Does Not Fit All?</p> <ul style="list-style-type: none"> • Computerized Games versus Crosswords Training in Mild Cognitive Impairment: The COG-IT trial - Davangere P. Devanand • Results from the Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT): A Personalized Approach - Kristine Yaffe • Impact of genetic risk in multidomain lifestyle preventive interventions - Alina Solomon • Effects of mindfulness training and exercise on cognitive function in healthy older adults without dementia: the MEDEX clinical trial - Eric J. Lenze
<p>Tuesday, July 18 9:15 a.m. Elicium 2</p>	<p>Proving The Evidence Base for Nationwide Caregiver Programs: Successes and Challenges</p> <ul style="list-style-type: none"> • Success and Challenges of Evaluation and Research within the Alzheimer's Association - Kristen Clifford • When One Call Isn't Enough: A Comparison of Alzheimer's Association Helpline Callers - Nancy A Hodgson • Strategy for Creating Evidence-based Educational Programs - Lauren Stratton • Managing Money: A Caregiver's Guide to Finances: A Pragmatic and Scalable Evidence-Based Program for Caregivers - Katherine Judge
<p>Tuesday, July 18 2:15 p.m. Elicium 2</p>	<p>Cognitive And Non-Cognitive Aspects Of Dementia</p> <ul style="list-style-type: none"> • Humanoid Mobile Robots and wearable sensors improve the quality of care and address worker shortages in nursing homes - Arshia a Khan • Ante-mortem cognitive trajectories of older adults with cerebrovascular disease across Aβ and tau biomarker profiles determined at autopsy in the National Alzheimer's Coordinating Center database - Emily Rosenich • Prevention of cognitive decline in subjective cognitive decline APOE-ϵ4 carriers after Epigallocatechin gallate and a multimodal intervention, the PENSA study: 1-year follow-up results of the randomized controlled trial - Laura Forcano • Microglial Activation Contributes to Neuropsychiatric Dysfunction in Alzheimer's Disease - Cristiano Schaffer Aguzzoli • Antidepressant exposure and long-term dementia risk in a nationwide study on U.S. Veterans with major depressive disorder - Jaime Ramos Cejudo • Prevalence and risk factors of the Motoric Cognitive Risk (MCR) Syndrome: Results from harmonized multi-country data sets - Oshadi Jayakody

<p>Tuesday, July 18 4:15 p.m. Elicium 2</p>	<p>Dyadic Patterns of Subjective Cognitive Change: Addressing Key Knowledge Gaps To Facilitate ADRD Research Along The Early Disease Continuum</p> <ul style="list-style-type: none"> • Associations between self and study partner report on the CFI with regional tau in a multi-cohort study - Michalina Jadick • Remote, unsupervised measurement of dyadic subjective cognitive change in the Brain Health Registry - Anna Aaronson • Increased worry associated with self-reported, but not informant-reported, subjective cognitive decline predicts risk of incident dementia - Katya T. Numbers • A novel approach to measure dyadic patterns of subjective cognitive changes: its association to Alzheimer's disease biomarkers and ability to predict clinical progression in cognitively normal older adults - Patrizia Vannini • Dyadic patterns of subjective cognitive decline relate to Alzheimer's disease biomarkers differently in preclinical and prodromal clinical states - Katherine A. Gifford • Predicting progression within the cognitive decline continuum using self- and partner-reported cognitive complaints, and depressive symptomatology in Cognitively Unimpaired (CU) and Subjective Cognitive Decline (SCD) participants: Evidence from the CompAS longitudinal study - Lucia Pérez-Blanco
<p>Wednesday, July 19 8:00 a.m. Hall 10</p>	<p>ALZ-NET: A Real World Data Platform To Inform The Future Of Alzheimer's Research, Treatment And Care</p>
<p>Wednesday, July 19 9:15 a.m. Hall 12</p>	<p>Novel Approaches To Address Caregiver Burden And Stress</p> <ul style="list-style-type: none"> • Promoting caregiver mastery in Black dementia caregivers - Glenna S Brewster • Caregiver needs: Lessons from the care ecosystem - Katherin Possin • Caregiving and caregiver burden in dementia home care - Gerhard Nikolaus Ransmayr • Factors influencing burden in adult-child and spousal caregivers - Kalisha Bonds Johnson
<p>Wednesday, July 19 2:15 p.m. Hall 5</p>	<p>World Alzheimer Report 2022: Dementia Treatment, Care And Support - Are Global Health Systems Ready For What's Next?</p> <ul style="list-style-type: none"> • World Alzheimer Report 2022 - How strong are global health systems: Lessons learned and case studies from across the globe - Wendy S Weidner . • From plan to impact: does a national dementia plan make a difference? Comparing post diagnostic care in England and Malaysia - Louise Robinson • Transitioning from dementia-related stigma to a Community Level Dementia Screening Program in Rural Kenya (DEM-SKY) - Christine W. Musyimi • Exploring dementia care pathways in seven LMICs with the help of case vignettes – identifying opportunities for strengthening pre- and post diagnostic support - Klara Lorenz-Dant • The Availability and Use of Anti-Dementia Drugs: An International Survey - Eugene Yee Hing Tang • How much would England's National Health Service have to invest to bring its capacity to deliver an Alzheimer's treatment to G7 average capacity levels? - Soeren Mattke
<p>Wednesday, July 19 4:15 p.m. Hall 5</p>	<p>Implementation Of Plasma AD Biomarkers In Diverse Community-Based And Primary Care Settings</p> <ul style="list-style-type: none"> • Road to implementation: patient and healthcare professional's perception of the blood test - Charlotte E. Teunissen • Alzheimer's disease blood tests of amyloid-β 42/40, p-tau217, p-tau181 and p-tau205 ratios in a diverse community-based population: Preliminary results from SEABIR - Randall J. Bateman • Blood Biomarkers Improve The Diagnostic Accuracy Of Alzheimer's Disease As Compared With Current Diagnostic Standard In the Primary Care Setting - Sebastian Palmqvist • Clinically relevant factors for blood-based Alzheimer biomarker interpretation - Henrik Zetterberg

Wednesday, July 19 4:15 p.m. Hall 12	Patient Access To Treatments For Alzheimer's Disease In The US and EU: A Comparative Public Policy Perspective
Thursday, July 20 8:00 a.m. Hall 3	The Complex Relationship Between TBI and ADRD <ul style="list-style-type: none"> • Traumatic Brain Injury and Cognitive Aging Among Older Veteran Men – A Twin Study Accounting for Genetics and Medical Conditions - Marianne Chanti-Ketterl • Impact of Dementia on Days at Home after Traumatic Brain Injury among Older Medicare Beneficiaries - Jennifer S Albrecht • The Bidirectional Association of TBI and Dementia/MCI among older US Veterans - Carrie Peltz • Brain Reserve Score on Acute Trauma Head CT is Correlated with Pre-TBI MCI/Dementia and is an Independent Predictor of Post-TBI Cognitive Outcome - Raquel C. Gardner
Thursday, July 20 8:00 a.m. Hall 11	Metabolic And Hormonal Connections To AD <ul style="list-style-type: none"> • Metformin and dietary restriction pathway are associated with neuroprotection in Alzheimer's disease context. A key role for glial autophagy - Flavia Eugenia Saravia • Relationship between metabolic disease and Alzheimer's disease - Zoe Arvanitakis • Synergistic effects of age at menopause and vascular risk on cognitive decline in postmenopausal women - Madeline Wood • Regulation of insulin entry into the brain - Elizabeth Rhea • Imaging the brain to assess brain insulin action - Stephanie Kullmann • Sphingomyelin 14:0 – the link between obesity and neuroinflammation - Roisin M. Mcmanus
Thursday, July 20 8:00 a.m. Hall 12	Modifiable Risk Factors And Multimorbidities In Dementia <ul style="list-style-type: none"> • Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: a population-based cohort study - Ilse E. M. vom Hofe • Ethnic Variation in Modifiable Risk Factors for Dementia - Phazha LK Bothongo • Proportion of Dementia Cases in the Oldest-old Attributable to 8 Neuropathological Changes: The 90+ Study - Maria M. M. Corrada • Patterns and trajectories of multimorbidity prior to dementia: a UK Biobank study - Raihaan Patel • New Anti-Hyperglycaemic Medications and the Risk of Dementia: A Nationwide Population-Based Study - Avi Cohen • Systolic Blood Pressure Levels and Probable Dementia : Secondary Analysis of a Randomized Clinical Trial - Byron C Jaeger
Thursday, July 20 8:00 a.m. Hall 2	New Clinical Candidates And Learnings From Anti-Amyloid Therapeutic Trials <ul style="list-style-type: none"> • Role of nutrition and metabolic regulation in multidomain trials for dementia risk reduction: findings from FINGER and FINGER 2.0 studies - Miia Kivipelto • Brain volume changes caused by anti-amyloid beta drugs and association with ARIA - Scott Ayton • Exposure-response modeling to describe the change in brain amyloid following lecanemab administration in patients with early Alzheimer's disease - Brian A. Willis • Effect of Concomitant Aducanumab on AD Clinical Trial Outcomes - Richard E Kennedy • [18F]PI2620 tau deposition increases along the Alzheimer's disease continuum in Down Syndrome and in presence of amyloid - Jordi Pegueroles • Blood-based biomarkers for clinical trials of Alzheimer's disease in Down syndrome - Juan Fortea
Thursday, July 20 11:30 a.m. Hall 11	Metabolic And Systemic Diseases: Associations With Dementia And Cognition <ul style="list-style-type: none"> • Investigating the impact of treatment timing on urinary tract infections in dementia at the population level - Helen Lai • The Brain Kidney Axis Vascular Cross Talk - Aditi Gupta

- | | |
|--|---|
| | <ul style="list-style-type: none">• Persistent Systemic Inflammation Mediates the non-Hispanic Black vs non-Hispanic White Disparity in Cognitive Function: A Longitudinal Analysis - Cesar Higgins• Associations between metabolic syndrome and markers of brain pathologies: the role of sex-differences - Anna Marseglia• The mediating effect of HbA1c levels on the relationship between education and cognitive function - Constantin Reinke• Association of kidney function with risk of incident dementia: a prospective cohort study of 275,167 UK Biobank participants - XinRui Wu |
|--|---|